David Roe, MD
Critical Care Medicine · Indianapolis, INNPI 1275593964
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,000 of the $6,538 with a category attached, or 91.8%. Eli Lilly accounts for 91.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $6,048 and has fallen 94.7% since, to $318 in 2025. Among critical care medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $384.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$6K
- Intuitive Surgical$208
- Insmed, Inc.$131
- Genentech USA, Inc.$86
- AstraZeneca$37
- Regeneron Healthcare Solutions, Inc.$25
- plus $50 from 3 others
What the payments were for
- Consulting fees$6,00092%
- Food & beverage$4417%
- Education$981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 1 | $6,000 |
| Intuitive Surgical | 2 | $208 |
| Insmed, Inc. | 6 | $131 |
| Genentech USA, Inc. | 2 | $86 |
| AstraZeneca | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Pfizer | 1 | $16 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,538 in reported general payments places this provider in the 90th percentile of 158 critical care medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 46 | $581,150 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 258 | $188,333 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $119,131 |
| Dupixent PenDupilumab | 28 | $103,698 |
| Spiriva RespimatTiotropium Bromide | 119 | $75,947 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 139 | $73,267 |
| Breo ElliptaFluticasone/Vilanterol | 110 | $67,833 |
| Spiriva HandihalerTiotropium Bromide | 89 | $55,143 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 88 | $53,586 |
| Pirfenidone | 30 | $32,248 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $27,237 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $17,540 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $16,549 |
| Arnuity ElliptaFluticasone Furoate | 61 | $16,156 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 53 | $8,778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $20 | $119,13112 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $37 | $33,91965 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 158 critical care medicine providers in Indiana.
Other critical care medicine in Indianapolis
- Vrushank PatelIndianapolis$142K
- Christopher KnieseIndianapolis$44K
- Stanley NasrawayIndianapolis$34K
- Ryan BoenteIndianapolis$15K
- Mark MastrodicasaIndianapolis$4K
- Bruce AckermanIndianapolis$3K
- Julio NoriegaIndianapolis$3K
- Nestor AnguianoIndianapolis$3K
- Tanya DevnaniIndianapolis$3K
- Damien PatelIndianapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.